Abstract: Objective This study was aimed at investigating clinical efficacy and safety of camrelizumab and sorafenibcombination therapy in the treatment of patients with advanced hepatocellular carcinoma (aHCC). Method 62 consecutive patients with aHCC were encountered in our hospital between January 2021 to January 2023, and we assigned them to receive camrelizumab and sorafenib combination or to receive sorafenib alone treatment. All patients were followed-up to September 30, 2023. Results Objective response rate was 41.9%, and disease control rate was 87.1%, both much higher than 16.1% and 64.5%(P<0.05) in the control; up to September 30, 9 patients (29.0%) in the combination group and 8 patients (25.8%, P>0.05) in sorafenib-treated group survived; in combination group, median progression free survival was 7.3 mon (95% CI:5.66-8.94), and overall survival was 15.6 mon(95% CI:11.84-19.34), while in the control, they were 4.9 mon(95%CI:3.92-5.88)and 10.1 mon(95% CI:8.59-11.71), both significantly different between the two groups (P<0.05);the incidence of immune thyroiditis was 25.8%, reactive cutaneous capillary hyperplasia was 32.2% and fatigue was 64.5% in the combination group, much higher than 0.0%, 0.0% and 35.5% (P<0.05) in the control. Conclusion Combination of camrelizumab and sorafenib in the treatment of patients with aHCC is encouraging, which might prolong survival and the adverse effect is under control.

Key words: Hepatocelluler carcinoma, Camrelizumab, Sorafenib, Therapy, Safety